3,4,5-Trimethoxycinnamic acid has anti-stress effect, prolonging the sleeping time in animals. 3,4,5-Trimethoxycinnamic acid may exert anti-seizure activity by acting at the GABAA/BZ receptor complex. It shows hypoxia inducible factor-2 (HIF-2) inhibitory activity with EC50 value of 60.6 uM. 3,4,5-Trimethoxycinnamic acid derivatives have a potential antinarcotic effect through acting as a 5-HT(1A) receptor agonist in mice.
1. Ramelteon significantly improves symptoms in patients with gastroesophageal reflux disease and significantly improves patients' sleep experience.
2. Ramelteon could be a potential therapeutic drug, in adjunctive treatment of learning and memory deficits seen in patients with schizophrenia.
3. Ramelteon is effective for the prevention of delirium, ramelteon administered nightly to elderly patients admitted for acute care may provide protection against delirium.
4. Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment, demonstrates no significant effects indicative of potential for abuse or motor and cognitive impairment at up to 20 times the recommended therapeutic dose.
Tryptophol is an aromatic alcohol found as a secondary product of alcoholic fermentation that induces sleep in humans. Tryptophol can inhibit the infection/replication of GVE2 by interacting with the host's Clp protease. Tryptophol can inhibit the proliferation of U937 cells by inducing apoptosis via a pathway involving caspase-8 followed by caspase-3. Tryptophol induces apoptosis through Death Receptor (DR) 5 and that the resistance of peripheral blood lymphocytes (PBL) to tryptophol-induced apoptosis might be due to competition from decoy receptor (DcR).